Catalyst Biosciences

Protease therapies for hemophilia, renal delayed graft function (DGF) & age-related macular degeneration (AMD)

placeSan Francisco, California, United States calendar_todayFounded 1997 groups45 employees language catalystbiosciences.com

Registered entities

Innovation

41 patent families (20 granted) — focus: Chemistry & metallurgy, Human necessities, Emerging technologies, Physics & computing; filing pace slowing. Cited 16,340 times.

YearFilings
201313
20146
201510
201610
20177
20186
20198
20205
20219
202211
20234
20242

Investor mix

27 investors on record; lead investors include Auriga Partners, Nomura, New Enterprise Associates, CDIB BioScience Venture Management; 2 have since exited.

Investor typeCountShare
Venture capital1763%
Private equity311%
Bank & private debt14%
Other / undisclosed622%
Coming soon